ADG106 injection + PD-1 antibody injection
Phase 1/2Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumor
Conditions
Solid Tumor, Non Hodgkin Lymphoma
Trial Timeline
Mar 11, 2021 → Feb 9, 2023
NCT ID
NCT04775680About ADG106 injection + PD-1 antibody injection
ADG106 injection + PD-1 antibody injection is a phase 1/2 stage product being developed by Adagene for Solid Tumor. The current trial status is terminated. This product is registered under clinical trial identifier NCT04775680. Target conditions include Solid Tumor, Non Hodgkin Lymphoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04775680 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Solid Tumor